Cloverleaf Bio
Drug Discovery · Oncology Therapeutics
$47.8Mtotal raised · 4 rounds on record
3open roles
$33Mlatest round · Seed · Sep 2026 · 2 mo ago
1backers · Draper Associates
Overview
Cloverleaf Bio is an early-stage therapeutics company developing a new class of engineered RNA therapeutics for cancer therapy. It hires scientists in in vivo cancer modeling and RNA biochemistry and research associates for animal experiments. The company is headquartered in New Haven, Connecticut, United States.
Key facts
As of Nov 13, 2026, Alion lists 3 open roles at Cloverleaf Bio. Cloverleaf Bio is headquartered in New Haven, United States. It was founded in 2023. It has raised $47.8M in 2 funding rounds. The latest round is Seed of $33M, announced in 2026.
- Open roles
- 3Its careers board, read on Nov 13, 2026
- Headquarters
- New Haven, United StatesAlion company profile, updated Nov 13, 2026
- Founded
- 2023Alion company profile, updated Nov 13, 2026
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $47.8MSum of 2 equity rounds Alion knows
- Latest round
- Seed · $33M · Sep 8, 2026Press report · globenewswire.com
- Technologies in its job postings
- 10Named in its job postings
Official records
Funding and backers
Total raised
$47.8M
4 rounds on record
Latest round
$33M
Seed · Sep 2026 · 2 mo ago
Team
51-200
employees, estimated range
Hiring now
3
open roles
Grants
$755k
2 grants · CORDIS
Backers
1
Draper Associates
The money's age
Fresh money
2 months since the last round · hiring slowed
Momentum
35/100
in the news, fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 8
Raised a round Seed $33M · globenewswire
Jul 1, 2025
Won a grant $355k · CORDIS
Jun 23, 2025
Won a grant $400k · CORDIS
2023
Founded
Tractionpublic signals, read monthly
Web presence
top 5%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Seed | Sep 2026 | $33M | — | globenewswire |
| Venture round | Aug 2026 | $14.8M | — | SEC Form D |
| Grant | Jul 2025 | $355k | — | CORDIS |
| Grant | Jun 2025 | $400k | — | CORDIS |
Registers and programsofficial lists and records that name the company
| Legal entity | Cloverleaf Bio, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Cole LewisExecutive OfficerSEC Form D
Austin DraycottExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Earli is a biotechnology company developing a BioAI approach to cancer therapy in which drugs are produced only in the tumor, by the tumor…
COMPANY Now is the time for surgical therapeutics Peptilogics is a clinical stage company advancing its lead engineered peptide, zaloganan…
Logic gated immunotherapies for cancer and autoimmune disease. Synolo Therapeutics is advancing a new class of therapeutics for cancer.
A bold visionfor genetic medicines AIRNA is committed to delivering the promise of RNA editing to people with rare diseases and common…
Oncobox Diagnostics: Personalized Cancer Therapy via Transcriptomics. Explore our research, clinical efficacy, and company overview.
RS & RS Scientific leads in cutting-edge cancer therapy research, developing innovative therapies for challenging cancer treatments. Their…
Jobs
≈ $54k – $115k per year (Estimated) · Equity · In office · Full-Time · 1+ year exp · Bachelor's Degree · Boston
CRISPR
qPCR
PCR
Western Blot
Cell Culture
Apply
≈ $106k – $243k per year (Estimated) · Equity · In office · Full-Time · PhD · Boston
Flow Cytometry
ELISA
Cell Culture
Immunohistochemistry
Apply
≈ $104k – $237k per year (Estimated) · Equity · In office · Full-Time · PhD · Boston
CLIP
Life Sciences
qPCR
PCR
Western Blot
Cell Culture
Next-Generation Sequencing
Apply
Growth
Hiring Momentum
37/100
Slowing
Open positions
3
0 opened / 0 closed in 30 days
Median time-to-fill
29 days
faster than 48% of the market
ATS activity
Every ~6 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
50% ▼
Biotech
50% ▲
Activity Timeline
Added Immunohistochemistry to stack
Oct 2026
Added Flow Cytometry to stack
Oct 2026
Added ELISA to stack
Oct 2026
Added Next-Generation Sequencing to stack
Oct 2026
Added Western Blot to stack
Oct 2026
Added qPCR to stack
Oct 2026
Added PCR to stack
Oct 2026
Added CRISPR to stack
Oct 2026
Added Cell Culture to stack
Oct 2026
People
Cole Lewis
Executive Officer
Austin Draycott
Executive Officer, Director
Christina Vorvis
Director
Dima Kuzmin
Director
Matthias Samwer
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
Technologies named in job postings at Cloverleaf Bio over the last 12 months, by layer, with the share of postings for each.
Technologies in use
10
Postings analysed
3
Stack modernity
54/100AI adopter
AI & ML
CLIP
Sign in to see how your skills match this stack
Sign In
Full Cloverleaf Bio tech stack
10 technologies · by team · pay by technology · changes · similar stacks
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Draper AssociatesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Cloverleaf Bio获种子轮投资_腾讯新闻
2026年9月9日美国tRNA癌症治疗药物研发商Cloverleaf Bio宣布完成种子轮融资本轮融资由4BIO Capital、AbbVie和BIVF联合投资具体融资金额未披露Cloverleaf Bio是一家专注于基于工程化转运RNAtRNA的新型癌症治疗药物研发的公司公司构建了工程化转运RNA药物平台旨在靶向肿瘤依赖的RNA修饰酶开发差异化癌症治...
Read more
Report
Cloverleaf Bio获得3300万美元种子轮融资_腾讯新闻
Cloverleaf Bio是一家tRNA癌症治疗药物研发服务商公司搭建工程化转运 RNA 药物平台靶向肿瘤依赖的 RNA 修饰酶核心管线 CLB-001 针对肝细胞癌在耐药实体瘤模型展现差异化活性同步布局抗体-tRNA 偶联物用于结直肠癌近日Cloverleaf Bio获得3300万美元种子轮融资4BIO Capital领投Boehringer Ingelheim Ven...
Read more
Report
Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer Therapeutics
Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer TherapeuticsOversubscribed round led by 4BIO Capital includes s...
Read more
Report
Cloverleaf Bio announced that it has received $33 million in funding from a group of investors
Read more
Report
Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer Therapeutics
Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer Therapeutics Oversubscribed round led by 4BIO Capital includes...
Read more
Report
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
1
Countries
1
Busiest office
Boston
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
New Haven
United States
HQ
Boston
United States
Regional office
3 open roles 4 posted in 90 days 33% engineering 50-200 est. staff
hires for Biotech, Science & Research
How to cite this page
Alion, "Cloverleaf Bio: key facts", as of Nov 13, 2026. https://alion.io/company/cloverleafbio
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0